New targeted agent produces considerable responses in patients with uterine cancer
(Dana-Farber Cancer Institute) The DNA repair-blocking drug adavosertib shrinks tumors in nearly one-third of patients in clinical trial data to be shared at the Society for Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Cancer of the Uterus | Clinical Trials | Gastroschisis Repair | Women